Mucormycosis

Disclaimer: > [!WARNING] Medical Disclaimer: This content is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional for diagnosis and treatment. Medical guidelines and best practices change rapidly; users should verify information with current local protocols.

1. Overview

Mucormycosis (formerly termed Zygomycosis) is a rare, life-threatening, rapidly progressive angioinvasive fungal infection caused by filamentous fungi of the order Mucorales (most commonly Rhizopus, Mucor, Rhizomucor, and Lichtheimia species). [1,2]

The disease predominantly affects severely immunocompromised individuals, particularly patients with uncontrolled diabetes mellitus (especially those in diabetic ketoacidosis), haematological malignancies with prolonged neutropenia, solid organ or haematopoietic stem cell transplant recipients, and patients receiving high-dose corticosteroid therapy. [3,4] The hallmark pathophysiological feature is direct fungal invasion of blood vessels leading to thrombosis, tissue infarction, and characteristic black necrotic eschars.

Mucormycosis is a medical and surgical emergency requiring immediate recognition and aggressive management. Despite optimal therapy combining high-dose antifungal agents, extensive surgical debridement, and reversal of immunosuppression, mortality rates remain devastatingly high at 50-80%, approaching 100% in cases with central nervous system involvement or when definitive treatment is delayed. [5,6] The surge in cases during the COVID-19 pandemic, particularly in India, has renewed global awareness of this lethal infection. [7]

---

2. Visual Summary Panel

Image Integration Plan

[!NOTE] Image Generation Status: Diagrams illustrating angioinvasive mechanisms and broad, aseptate, ribbon-like hyphae with right-angle branching patterns are queued.

Mucormycosis vs Aspergillosis: Key Histopathological Distinctions

---

3. Epidemiology

Incidence and Prevalence

Mucormycosis is a rare infection with significant geographic variation. Global incidence is estimated at 0.005-1.7 per million population annually, although true rates are likely underestimated due to diagnostic challenges and limited surveillance systems. [8] The highest burden occurs in India, where prevalence is approximately 70 times higher than in developed countries (estimated 0.14 per 1000 vs 0.002 per 1000), attributed to high rates of uncontrolled diabetes and limited access to healthcare. [9]

The COVID-19 pandemic resulted in an unprecedented surge, particularly in India with over 51,000 cases reported during 2021, representing a 10-20 fold increase from baseline. This was attributed to the convergence of multiple risk factors: corticosteroid therapy for COVID-19, COVID-associated immune dysregulation, pre-existing diabetes, and in some regions, use of industrial oxygen contaminated with fungal spores. [7,10]

Mortality Rates

Mucormycosis carries one of the highest mortality rates among invasive fungal infections:

Mortality approaches 100% in patients with:

• Central nervous system involvement with cavernous sinus thrombosis or brain abscess
• Disseminated disease
• No surgical intervention
• Delayed diagnosis (>6 days from symptom onset to treatment)
• Persistent neutropenia or uncontrolled immunosuppression [5,6]

Risk Factors and Predisposing Conditions

Mucormycosis is almost exclusively a disease of the immunocompromised. Key risk factors include:

1. Diabetes Mellitus (Most Common Worldwide)

• Present in 40-88% of rhinocerebral mucormycosis cases [9,12]
• Diabetic ketoacidosis (DKA) is the single strongest risk factor
• Mechanism: Acidosis releases iron from transferrin; hyperglycaemia impairs neutrophil function
• Risk persists even after correction of acidosis for 24-48 hours

2. Haematological Malignancies

• Most common risk factor in Europe/USA (30-40% of cases) [6]
• Particularly acute myeloid leukaemia, myelodysplastic syndrome
• Risk associated with prolonged neutropenia (ANC less than 500 for >10 days)
• High-dose chemotherapy-induced mucosal injury facilitates fungal entry

3. Haematopoietic Stem Cell and Solid Organ Transplantation

• Accounts for 10-20% of cases [13]
• Highest risk in first 6 months post-transplant
• Allogeneic HSCT > autologous HSCT
• Lung and liver transplants particularly high risk

4. Corticosteroid Therapy

• Present in 50-60% of cases (often overlapping with other risk factors) [14]
• Dose-dependent risk: high-dose (≥40 mg prednisone equivalent daily for ≥2 weeks)
• Impairs macrophage and neutrophil function
• Major contributing factor in COVID-19-associated mucormycosis

5. Iron Overload

• Thalassaemia major, haemochromatosis, multiple transfusions
• Deferoxamine (iron chelator) therapy: Paradoxically INCREASES risk [15]
• Mechanism: Deferoxamine acts as a siderophore, providing iron directly to Mucorales fungi
• Alternative chelators (deferasirox, deferiprone) do NOT have this effect

6. Other Risk Factors

• Trauma (especially natural disasters - "tornado wounds") [16]
• Burns (cutaneous mucormycosis)
• Malnutrition, particularly protein-energy malnutrition
• HIV/AIDS (rare; CD4 less than 50)
• Chronic kidney disease (uraemia-associated immune dysfunction)
• Intravenous drug use (contaminated needles)
• Premature neonates (gastrointestinal form)

Demographics

• Age: Bimodal distribution - peaks in 5th-6th decade (diabetes-related) and in neonates/young children (haematological malignancy)
• Sex: Male predominance (M:F ratio 2-3:1), likely reflecting higher rates of diabetes and smoking in males [9]
• Ethnicity: Higher incidence in South Asian populations (diabetes prevalence), no intrinsic genetic susceptibility identified

Temporal Trends

• Incidence rising globally over past 2 decades (1.2-fold increase per decade) [8]
• Contributing factors: Increased use of immunosuppressive therapies, better recognition, improved diagnostic techniques
• Seasonal variation observed in some regions (monsoon season in India - environmental spore burden)

---

4. Aetiology and Pathophysiology

Causative Organisms

Mucormycosis is caused by filamentous fungi belonging to the order Mucorales within the subphylum Mucoromycotina. These are ubiquitous environmental saprophytes found in soil, decaying organic matter, bread, and air. [1]

Most Common Species (in descending frequency):

1. Rhizopus arrhizus (R. oryzae) - 60-70% of cases
2. Mucor species - 10-20%
3. Rhizomucor species - 5-10%
4. Lichtheimia (formerly Absidia) species - 5-10%
5. Cunninghamella bertholletiae - rare, high mortality
6. Apophysomyces species - primarily post-traumatic cutaneous

Routes of Infection

Pathophysiological Mechanisms

Step 1: Spore Deposition and Germination

Mucorales spores (sporangiospores, 3-11 μm diameter) are ubiquitous in the environment and inhaled daily by healthy individuals without consequence. [1] In immunocompromised hosts, impaired phagocytic clearance allows spores to germinate into invasive hyphae.

Key Immune Defects:

• Neutrophils: Primary defence mechanism - kill spores via oxidative burst
• Macrophages: Ingest and destroy spores through acidification and reactive oxygen species
• Deficiency states: Neutropenia, corticosteroid-induced dysfunction, DKA-associated impairment

Step 2: Hyphal Invasion and Angioinvasion

Unlike Aspergillus, which invades through intercellular spaces, Mucorales exhibit direct invasion through epithelium and blood vessel walls, a process facilitated by:

1. Fungal-Expressed Proteases and Lipases:

   • CotH proteins (invasins) on fungal surface bind to GRP78 (glucose-regulated protein 78) on mammalian endothelial cells [17]
   • Facilitates adherence and active penetration of endothelium
   • Enhanced expression during acidosis and hyperglycaemia

2. Thermotolerance: Mucorales thrive at 37°C and in acidic conditions (pH 5-7), unlike most environmental fungi

3. Iron Acquisition: Mucorales possess high-affinity iron uptake systems

   • In DKA: Acidosis → iron dissociates from transferrin → free iron available
   • Ketone bodies directly enhance fungal growth
   • Deferoxamine acts as a xenosiderophore, delivering iron directly to fungus [15]

Step 3: Vascular Thrombosis and Tissue Necrosis

The hallmark of mucormycosis pathology is angioinvasion:

1. Hyphae penetrate elastic lamina of arteries (medium and large vessels)
2. Intravascular hyphal proliferation
3. Thrombosis formation - mechanical obstruction + platelet activation
4. Vessel occlusion → ischaemic infarction
5. Tissue necrosis - characteristic black eschars (infarcted, non-viable tissue)

Consequences:

• Destruction of surrounding tissue
• Haemorrhage (vessel wall necrosis)
• Spread along vascular planes (explains rapid progression)
• Limited inflammatory response (due to ischaemia and immunosuppression)

Step 4: Contiguous and Haematogenous Spread

Rhinocerebral Progression:

1. Nasal/sinus mucosa →
2. Palate/turbinates →
3. Orbit (via ethmoid sinuses) →
4. Cavernous sinus (via ophthalmic vessels) →
5. Internal carotid artery →
6. Brain parenchyma (frontal/temporal lobes)

Pulmonary Progression:

1. Bronchial mucosa →
2. Pulmonary vessels →
3. Lung parenchyma (infarction, cavitation) →
4. Haematogenous dissemination

Molecular Pathophysiology in Diabetic Ketoacidosis

DKA creates a "perfect storm" for mucormycosis through multiple convergent mechanisms:

Iron Metabolism Dysfunction

• Normal state: Serum iron tightly bound to transferrin (prevents microbial utilization)
• DKA/acidosis: Low pH disrupts iron-transferrin binding
• Result: ↑ Free serum iron (up to 10-fold increase)
• Mucorales fungi have high-affinity reductive iron assimilatory systems that preferentially acquire free iron
• Iron is essential for rhizoferrin production (fungal siderophore)

Ketone Body Effect

• β-hydroxybutyrate and acetoacetate directly enhance Rhizopus growth in vitro [18]
• Mechanisms not fully elucidated but may involve:
  • Alternative carbon source
  • Upregulation of fungal metabolic pathways
  • Enhanced spore germination

Neutrophil Dysfunction

• Hyperglycaemia impairs:
  • Chemotaxis (reduced migration to infection site)
  • Phagocytosis (decreased ingestion of spores)
  • Oxidative burst (reduced superoxide production)
• Acidosis further depresses neutrophil function
• Effects persist 24-48 hours after correction of DKA

Endothelial Receptor Upregulation

• Hyperglycaemia and acidosis → ↑ GRP78 expression on endothelial cells [17]
• GRP78 is the mammalian receptor for CotH (fungal invasin)
• Result: Enhanced fungal adherence and invasion

Host Immune Response (or Lack Thereof)

In immunocompetent hosts:

• Alveolar macrophages and neutrophils rapidly eliminate spores
• Minimal to no infection

In immunocompromised hosts:

• Inadequate innate immunity → spore germination
• Angioinvasion → tissue ischaemia → poor inflammatory cell recruitment
• "Cold" infection - minimal purulence or inflammation
• Necrotic tissue provides substrate for ongoing fungal proliferation

---

5. Clinical Presentation

Mucormycosis manifests in six major clinical forms, determined by the site of spore inoculation and the patient's underlying condition. Rhinocerebral is the most common form worldwide (40-49% of cases), while pulmonary predominates in haematology/oncology patients (20-30%). [5,6]

5.1 Rhinocerebral Mucormycosis (40-49% of cases)

Typical Patient: Diabetic in DKA, often middle-aged to elderly

Pathophysiology: Spore inhalation → germination in nasal/sinus mucosa → local invasion → spread to orbit/brain via vascular and neural pathways

Early Features (Days 1-3)

• Facial pain (unilateral, severe, "boring" quality) - often initial symptom
• Nasal congestion and discharge (blood-tinged, serosanguinous)
• Headache (frontal, periorbital)
• Low-grade fever (may be absent in diabetes)
• Hyposmia/anosmia (nasal obstruction)

Sinonasal Examination Findings

• Black eschar on nasal turbinates (middle > inferior), septum, or palate - PATHOGNOMONIC [12]
• Mucosal pallor or dusky discolouration (pre-necrotic)
• Ulceration and crusting
• Epistaxis (vessel erosion)
• Foul-smelling discharge

Orbital Involvement (50-70% of rhinocerebral cases)

• Periorbital oedema and erythema (may mimic orbital cellulitis)
• Proptosis (globe displacement)
• Ophthalmoplegia - cranial nerve palsies:
  • III (oculomotor) - ptosis, mydriasis, "down and out" gaze
  • IV (trochlear) - vertical diplopia
  • VI (abducens) - lateral gaze palsy (early sign)
• Vision loss - progressive, irreversible if not urgently treated
  • "Mechanisms: Central retinal artery occlusion, optic nerve infarction, ophthalmic artery thrombosis"
• Orbital Apex Syndrome: Total ophthalmoplegia + blindness + trigeminal (V1, V2) sensory loss
• Chemosis (conjunctival oedema)
• Fixed, dilated pupil (late, ominous sign)

Cerebral Extension (30-40% of rhinocerebral cases)

• Altered mental status (confusion, lethargy → coma)
• Seizures (focal or generalized)
• Hemiparesis/hemiplegia (internal carotid or MCA territory infarction)
• Cranial nerve V palsies:
  • "V1 (ophthalmic): Forehead/scalp numbness"
  • V2 (maxillary): Cheek/upper lip numbness ("numb cheek syndrome")
  • "V3 (mandibular): Lower lip/jaw numbness"
• Cavernous sinus thrombosis - bilateral findings, severe headache, papilloedema
• Brain abscess (frontal, temporal lobes)
• Internal carotid artery thrombosis - massive stroke, often fatal

Hard Palate Necrosis

• Black eschar on hard palate - classical finding [12]
• Indicates bone involvement (maxillary bone necrosis)
• May progress to oro-antral fistula

5.2 Pulmonary Mucormycosis (20-30% of cases)

Typical Patient: Haematological malignancy with neutropenia, HSCT recipient, leukaemia patients

Pathophysiology: Spore inhalation → tracheobronchial invasion → angioinvasion → pulmonary infarction → cavitation

Clinical Features

• Fever (persistent, unresponsive to antibacterials)
• Cough (dry or productive)
• Haemoptysis - CLASSIC and ominous feature [11]
  • Indicates vascular invasion and erosion
  • Ranges from blood-streaked sputum to massive haemoptysis
  • Can be fatal (exsanguination)
• Pleuritic chest pain (pulmonary infarction)
• Dyspnoea (progressive, reflecting extent of lung involvement)

Examination Findings

• Often minimal or non-specific (consolidation, reduced air entry)
• Pleural rub (if infarction extends to pleura)
• Respiratory distress in advanced disease

Radiological Features (See Investigations section)

• "Reverse halo sign" or "atoll sign" (central ground-glass opacity surrounded by consolidation) - suggestive but not specific
• Wedge-shaped consolidation (infarction)
• Cavitation (especially in recovering neutrophil counts)
• Pleural effusion (often haemorrhagic)
• Rapid progression over 24-48 hours

5.3 Cutaneous Mucormycosis (10-16% of cases)

Typical Patient: Trauma, burns, surgical wounds, immunosuppressed patients, IV drug users

Pathophysiology: Direct inoculation → local invasion → necrosis (isolated) OR haematogenous spread to skin (disseminated disease)

Clinical Features

Isolated Cutaneous (better prognosis):

• Indurated, erythematous plaque at inoculation site
• Progression to necrotic eschar with central black discolouration
• Violaceous border
• Rapid expansion (hours to days)
• Minimal pain (due to tissue necrosis and nerve involvement)
• Satellite lesions may develop

Disseminated with Skin Involvement (poor prognosis):

• Multiple lesions in different anatomical sites
• No clear trauma history
• Rapidly progressive
• Associated with systemic features of disseminated disease

Special Forms:

• "Tornado wounds": Post-disaster (natural catastrophes), soil contamination, necrotising fasciitis-like presentation [16]
• Neonatal: Umbilical stump, adhesive tape sites

5.4 Gastrointestinal Mucormycosis (2-11% of cases)

Typical Patient: Premature neonates, severely malnourished children, immunosuppressed adults

Pathophysiology: Ingestion of spores → mucosal invasion → bowel wall necrosis → perforation

Clinical Features

• Non-specific abdominal pain (poorly localised)
• Nausea and vomiting
• Abdominal distension
• Gastrointestinal bleeding (haematemesis, melaena, haematochezia)
• Peritonitis (bowel perforation)
• Bowel obstruction (rare)

Most commonly involves stomach > colon > ileum

Diagnosis: Extremely difficult pre-operatively; often found at laparotomy for "acute abdomen"

Prognosis: 85-100% mortality [11] due to late diagnosis and extensive disease at presentation

5.5 Disseminated Mucormycosis (6-12% of cases)

Definition: Involvement of ≥2 non-contiguous organ systems OR positive blood culture (exceedingly rare)

Typical Patient: Profound immunosuppression (HSCT, leukaemia with prolonged neutropenia)

Pathophysiology: Haematogenous spread from any primary site (lung > sinus > skin > GI)

Clinical Features

• Multi-organ dysfunction
• Persistent fever despite broad-spectrum therapy
• CNS involvement: Meningitis, brain abscess, focal neurological deficits
• Renal involvement: Infarction, abscess
• Skin lesions: Multiple necrotic papules/nodules (40% of disseminated cases)
• Spleen, liver involvement: Abscesses
• Endocarditis (rare, catastrophic)

Diagnosis: Requires high index of suspicion; tissue biopsy from multiple sites

Prognosis: 90-100% mortality [5,6]

5.6 Uncommon Forms

Cardiovascular

• Endocarditis (prosthetic > native valves)
• Myocardial abscess
• Pericarditis

Renal

• Isolated renal mucormycosis (pyelonephritis, abscess)
• Often from disseminated disease

Bone and Joint

• Osteomyelitis (contiguous spread from sinus infection or post-trauma)
• Septic arthritis (rare)

---

6. Differential Diagnosis

Prompt recognition of mucormycosis is critical, as it is easily confused with more common conditions. The differential varies by clinical presentation:

6.1 Rhinocerebral Presentation

1. Invasive Aspergillosis (Most Common Confusion)

Critical Point: Starting empiric voriconazole for presumed aspergillosis can be FATAL if the patient has mucormycosis (no activity against Mucorales and may delay appropriate therapy). [19]

2. Bacterial Sinusitis and Orbital Cellulitis

• More common, gradual onset
• Responds to antibiotics (initial improvement before deterioration in mucormycosis)
• No necrotic eschars
• CT: Sinus opacification but no bone destruction
• Purulent discharge (vs serosanguinous in mucormycosis)

3. Cavernous Sinus Thrombosis (Septic)

• Can result FROM mucormycosis or mimic it
• Bilateral findings more common
• Headache, ophthalmoplegia, altered mental status
• MRI with contrast differentiates (filling defect in cavernous sinus)

4. Rhinocerebral Actinomycosis/Nocardiosis

• Chronic, indolent course (weeks to months)
• "Sulfur granules" (Actinomyces)
• Responds to prolonged antibiotics
• No rapid progression

5. Malignancy (Sinonasal, Orbital)

• Nasopharyngeal carcinoma, lymphoma, rhabdomyosarcoma
• Subacute presentation (weeks)
• Mass effect on imaging
• Biopsy shows malignant cells

6. Wegener's Granulomatosis (Granulomatosis with Polyangiitis)

• Nasal crusting, septal perforation
• Positive c-ANCA/PR3
• Chronic course
• Granulomatous inflammation on biopsy

6.2 Pulmonary Presentation

1. Invasive Pulmonary Aspergillosis - Most important differential

• Same risk factors (neutropenia)
• "Halo sign" early, "air crescent sign" late (vs reverse halo in mucormycosis)
• Galactomannan assay positive (negative in mucormycosis)
• Histopathology distinguishes

2. Bacterial Pneumonia (Gram-negative, Staph)

• Cavitating pneumonia (Klebsiella, Pseudomonas, S. aureus)
• More rapid response to antibiotics
• Sputum cultures positive

3. Pulmonary Embolism with Infarction

• Wedge-shaped opacities
• Haemoptysis
• CTPA shows filling defect
• D-dimer elevated

4. Lung Abscess

• Air-fluid level
• Anaerobic bacteria
• Chronic course

6.3 Cutaneous Presentation

1. Necrotising Fasciitis (Bacterial)

• Streptococcal/Clostridial
• More pain (severe, out of proportion)
• Crepitus (gas-forming organisms)
• Rapid systemic toxicity
• Responds to antibiotics + surgery

2. Cutaneous Aspergillosis

• Similar appearance
• Histopathology differentiates

3. Ecthyma Gangrenosum (Pseudomonas)

• Classically in neutropenic patients
• Blood cultures often positive
• Histology: bacteria, not fungi

4. Pyoderma Gangrenosum

• Autoimmune/inflammatory
• Painful ulcers with violaceous borders
• Responds to immunosuppression (NOT surgery)
• Histology: neutrophilic inflammation

---

7. Investigations

7.1 First-Line Investigations

Imaging: CT or MRI Sinuses and Orbit (Immediate)

Indications: Any suspected rhinocerebral mucormycosis

CT Findings:

• Sinus opacification (air-fluid levels, mucosal thickening)
• Bone erosion/destruction - EARLY finding, distinguishes from bacterial sinusitis [12]
  • Medial orbital wall (lamina papyracea)
  • Cribriform plate
  • Maxillary sinus walls
• Peri-antral fat stranding
• Orbital involvement: Proptosis, extra-ocular muscle thickening
• Intracranial extension: Loss of grey-white differentiation, mass effect

MRI Findings (Superior for soft tissue and intracranial extension):

• T1: Hypointense signal in involved sinuses
• T2: Variable - hyperintense (early) to hypointense (necrosis, fungal elements, desiccated mucus)
• T1 + Gadolinium:
  • "Black turbinate sign: Non-enhancing turbinate (infarction) - HIGHLY SPECIFIC [20]"
  • Non-enhancing sinonasal mucosa (vs enhancement in bacterial infection)
• Cavernous sinus thrombosis: Filling defect, expansion
• Vascular involvement: Loss of flow voids in ICA
• Brain extension: Abscesses (ring-enhancing), infarction (diffusion restriction)

MR Angiography: Assess vessel patency (ICA, ophthalmic artery)

Imaging: Chest CT (for pulmonary cases)

Findings Suggestive of Mucormycosis:

• Reverse halo sign (atoll sign): Central ground-glass opacity with surrounding consolidation [11]
  • 20-30% of pulmonary mucormycosis
  • "Also seen in: Organizing pneumonia, Wegener's, other fungi"
• Wedge-shaped consolidation (infarction)
• Nodules with "halo sign" (early)
• Cavitation (develops as neutrophils recover - "air crescent sign")
• Pleural effusion (often haemorrhagic on thoracentesis)
• Rapid progression over 24-48 hours (distinguishes from aspergillosis)

Laboratory Tests

Essential:

• Full blood count: Assess neutropenia
• Blood glucose, HbA1c: Identify/quantify diabetes
• Arterial blood gas: Assess acidosis (DKA, metabolic acidosis)
• Renal function: Baseline for amphotericin B therapy
• Electrolytes: Particularly potassium (amphotericin toxicity)
• Liver function tests: Baseline
• Iron studies: Especially if on deferoxamine

Fungal Biomarkers (Limited Utility):

• Serum galactomannan: NEGATIVE in mucormycosis (Aspergillus-specific)
• Serum (1,3)-β-D-glucan: NEGATIVE or low (Mucorales lack significant β-glucan in cell wall)
• Serum Mucorales PCR: Experimental, not widely available, low sensitivity (40-60%)

Negative fungal biomarkers in suspected invasive fungal infection should raise suspicion for mucormycosis.

7.2 Definitive Diagnostic Investigations

Tissue Biopsy (GOLD STANDARD)

Urgency: Should be obtained within 24 hours of clinical suspicion

Sites:

• Nasal endoscopy with biopsy (rhinocerebral)
• Bronchoscopy with BAL and transbronchial biopsy (pulmonary)
• Surgical debridement specimens (any site)
• Skin punch biopsy (cutaneous)

Sample Handling:

• Fresh tissue in sterile saline (NOT formalin) for culture
• Separate sample in formalin for histopathology
• Large sample volume (fungi may be focal)

Histopathological Features (Diagnostic)

Direct Microscopy (KOH mount, calcofluor white):

• Broad (6-25 μm), ribbon-like hyphae
• Aseptate (non-septate) or irregularly septate
• Right-angle branching (90°) or irregular branching
• Thin-walled, easily fragmented
• Angioinvasion: Hyphae seen within and surrounding blood vessels

Histopathology (H&E, PAS, GMS stains):

• PAS (Periodic Acid-Schiff) and GMS (Grocott-Gomori Methenamine Silver) stain hyphae dark
• Vascular invasion with thrombosis
• Tissue necrosis (infarction)
• Minimal inflammatory response (immunosuppression + ischaemia)

Distinguishing Mucorales from Aspergillus on Histology:

Critical Exam Point: If asked about histopathology of invasive fungal infection, ALWAYS describe: hyphal width, septation, branching angle, and angioinvasion. These four features allow differentiation.

Fungal Culture

Challenges:

• Low sensitivity (50-60%): Mucorales are fragile and easily destroyed during tissue processing
• Slow growth: 2-7 days (vs 24-48h for bacteria)
• Requires specialized mycology lab

Culture Media:

• Sabouraud Dextrose Agar
• Potato Dextrose Agar

Identification:

• Colony morphology: Rapid-growing, cottony, white-grey colonies
• Microscopy: Sporangiophores, sporangia, rhizoids (genus-specific)
• Molecular identification: ITS sequencing (genus and species level)

Critical Point: DO NOT WAIT for culture results to initiate therapy. Empiric treatment must begin based on clinical and histological suspicion.

7.3 Additional Investigations

Nasal Endoscopy

• Direct visualization of necrotic tissue, eschars
• Guided biopsy
• Assessment of extent (turbinates, septum, palate)

Ophthalmology Examination

• Visual acuity
• Pupillary reflexes (APD - afferent pupillary defect)
• Extraocular movements
• Fundoscopy (retinal artery occlusion, optic disc oedema)
• Intraocular pressure

Lumbar Puncture (if CNS involvement suspected)

• CSF analysis (usually non-specific)
• CSF fungal culture and PCR (low yield)
• Primarily to exclude bacterial/viral meningitis

Audiometry

• If temporal bone involvement suspected

---

8. Classification

There is no universally accepted staging system for mucormycosis severity. Classification is primarily anatomical, based on site of involvement:

Anatomical Classification

1. Rhinocerebral (40-49%)

   • Rhino-orbital (confined to sinuses and orbit)
   • Rhino-orbito-cerebral (intracranial extension)

2. Pulmonary (20-30%)

3. Cutaneous (10-16%)

   • Isolated (localized)
   • Disseminated with cutaneous manifestations

4. Gastrointestinal (2-11%)

5. Disseminated (6-12%) - ≥2 non-contiguous sites

6. Uncommon isolated sites (1-5%): Renal, cardiac, bone, etc.

Prognostic Classification (Informal)

---

9. Management

Fundamental Principle: Mucormycosis management is based on TRIPLE THERAPY:

1. Rapid initiation of antifungal therapy (liposomal amphotericin B)
2. Aggressive surgical debridement (early, extensive, often repeated)
3. Reversal of underlying predisposing factors (correct DKA, reduce immunosuppression)

All three components are essential. Failure to implement any component dramatically worsens outcomes.

---

9.1 Antifungal Therapy

First-Line: Liposomal Amphotericin B (L-AmB)

Agent of Choice: Liposomal amphotericin B (L-AmB, AmBisome) [1,2]

Dosing:

• Standard: 5 mg/kg IV daily
• High-dose: 10 mg/kg IV daily - recommended for CNS involvement or severe disease [19]
• Duration: Minimum 4-6 weeks; often 6-12 weeks depending on clinical response

Why Liposomal Formulation?

• Higher tissue penetration (lipid formulation allows higher doses)
• Reduced nephrotoxicity compared to amphotericin B deoxycholate
• Achieves higher serum and tissue concentrations
• Essential for CNS penetration at 10 mg/kg dose

Alternative: Amphotericin B lipid complex (ABLC, Abelcet) 5-7.5 mg/kg/day - if L-AmB unavailable

Monitoring During Amphotericin Therapy:

• Renal function: SCr, eGFR (daily initially, then twice weekly)
• Electrolytes: Particularly potassium and magnesium (risk of hypokalaemia, hypomagnesaemia)
  • "Supplement aggressively: KCl, MgSO4"
• Full blood count: Monitor for anaemia
• Liver function tests: Weekly
• Infusion-related reactions: Fever, rigors, hypotension
  • "Premedication: Paracetamol, antihistamine ± hydrocortisone (if severe)"

Duration of Therapy:

• Continue until:
  1. Resolution of clinical signs and symptoms
  2. Resolution of immunosuppression (neutrophil recovery, off steroids, DKA corrected)
  3. Radiological improvement (may lag clinical improvement)
• Minimum 6 weeks, often 12 weeks or longer
• Cumulative dose often exceeds 3-5 grams

Exam Viva Point - Amphotericin B Dosing:

"I would start liposomal amphotericin B at 10 mg/kg IV daily for CNS or severe disease, or 5 mg/kg for limited disease. This is the ONLY first-line agent with proven efficacy. I would closely monitor renal function and electrolytes, particularly potassium, and supplement as needed. Therapy duration is typically 6-12 weeks, guided by clinical and radiological response."

Alternative/Adjunct: Isavuconazole

Agent: Isavuconazole (Cresemba) - a triazole with Mucorales activity [19]

Role:

• Step-down therapy after initial amphotericin response (de-escalation)
• Primary therapy if amphotericin contraindicated (renal failure)
• Salvage therapy for amphotericin-refractory disease
• Combination therapy with amphotericin (some experts, no RCT data)

Dosing:

• Loading: 200 mg IV/PO three times daily for 6 doses (first 48 hours)
• Maintenance: 200 mg IV/PO once daily

Advantages:

• Oral bioavailability (allows outpatient therapy)
• Better tolerability than amphotericin
• No renal toxicity
• Therapeutic drug monitoring not routinely required

Disadvantages:

• Less clinical data than amphotericin
• More expensive
• Not superior to amphotericin as first-line

Typical Use: Start amphotericin, achieve clinical stability (2-4 weeks), then switch to isavuconazole for completion of 8-12 week total course

Salvage Therapy: Posaconazole

Agent: Posaconazole (Noxafil) - triazole with Mucorales activity

Role:

• Salvage therapy (disease progression despite amphotericin + surgery)
• Step-down/continuation therapy (alternative to isavuconazole)
• Prophylaxis in high-risk patients (haematology, HSCT)

Dosing:

• Delayed-release tablets or IV:
  • "Loading: 300 mg twice daily on Day 1"
  • "Maintenance: 300 mg once daily"
• Oral suspension: 200 mg four times daily or 400 mg twice daily (inferior absorption)

Note:

• Requires therapeutic drug monitoring (target trough >1 mg/L, ideally >1.5 mg/L)
• Significant drug interactions (CYP3A4 substrate)

Combination Therapy

Concept: Amphotericin B + azole (isavuconazole or posaconazole)

Evidence:

• Retrospective data suggests possible benefit [2]
• No randomized controlled trials
• Some experts use for severe/refractory disease
• Current consensus: May consider for salvage, but not routine first-line

Agents with NO Activity Against Mucorales (Critical)

• Voriconazole: NO ACTIVITY - must NEVER be used [19]
  • Major contributor to increased mucormycosis cases in aspergillosis-endemic units
• Fluconazole: No activity
• Echinocandins (caspofungin, micafungin, anidulafungin): NO ACTIVITY
  • Mucorales lack sufficient β-1,3-glucan in cell wall

Critical Error: Empiric voriconazole for "mould infection" in a patient with unrecognized mucormycosis results in disease progression and death.

---

9.2 Surgical Management

Principle: "Surgery is as important as antifungals" - mortality is 2-3 times higher without surgery [5,6]

Indications for Surgery

Absolute:

• All cases of rhinocerebral mucormycosis
• Pulmonary mucormycosis (if surgically accessible)
• Cutaneous mucormycosis (debridement essential)

Relative:

• Disseminated disease (debulk accessible sites)

Surgical Approach: Aggressive Debridement

Goal: Remove ALL necrotic and infected tissue until bleeding, viable tissue is encountered

Rhinocerebral Surgery:

1. Endoscopic Sinus Surgery (ESS) - Initial approach

   • Removal of necrotic turbinates, septum, sinus mucosa
   • Wide antrostomy, ethmoidectomy, sphenoidotomy
   • Removal of affected bone (lamina papyracea, skull base if involved)

2. Extended Procedures (if limited ESS inadequate):

   • Maxillectomy (partial or total) - removal of maxillary bone/sinus
   • Orbital exenteration - complete removal of eye, orbital contents, periosteum
     • Indications:
       • Retrobulbar involvement
       • Orbital apex involvement
       • Vision already lost (irreversible)
       • Cavernous sinus thrombosis
   • Craniofacial resection - if skull base/dura involved

3. Repeat Debridement:

   • Often required daily to every 48 hours until no further necrosis
   • Assess intraoperatively and with repeat imaging

Pulmonary Surgery:

• Lobectomy or wedge resection - if localized, surgically accessible
• Indications:
  • Single lobe involvement
  • Accessible lesion
  • Reasonable pulmonary reserve
  • Refractory to medical therapy or high bleeding risk (massive haemoptysis)
• Caution: High perioperative mortality in neutropenic patients

Cutaneous Surgery:

• Wide debridement to bleeding margins
• May require skin grafting or flaps for reconstruction

Timing:

• Urgent: Within 24-48 hours of diagnosis
• Delay >6 days from symptom onset associated with doubled mortality [6]

Multidisciplinary Team:

• ENT/Head-Neck Surgery
• Ophthalmology
• Neurosurgery (if intracranial extension)
• Maxillofacial Surgery
• Cardiothoracic Surgery (pulmonary cases)
• Plastic Surgery (reconstruction)

Exam Viva Point - Surgical Decision-Making:

"Surgical debridement is MANDATORY and should be performed within 24 hours. The goal is to remove all necrotic tissue until healthy, bleeding tissue is reached. This often requires extensive resection including maxillectomy or even orbital exenteration if the orbit is involved and vision is lost. I would arrange daily reassessment and repeat debridement as needed. Surgery must be combined with high-dose amphotericin B—neither alone is sufficient."

---

9.3 Reversal of Underlying Predisposing Factors

Principle: Address the immune defect that allowed infection

1. Diabetic Ketoacidosis Management

Goals:

• Correct acidosis - target pH >7.30 (normalizes iron binding)
• Achieve euglycaemia - target glucose 6-10 mmol/L
• Continue tight glucose control throughout treatment

Actions:

• IV insulin infusion (standard DKA protocol)
• IV fluids (correct dehydration)
• Electrolyte replacement
• Monitor pH, glucose every 1-2 hours initially

Timeline: Acidosis correction reduces fungal growth stimulus within 12-24 hours but neutrophil function may take 48 hours to normalize

2. Corticosteroid Reduction/Cessation

Goal: Minimize immunosuppression while balancing underlying disease

Actions:

• Taper corticosteroids as rapidly as underlying condition allows
• Discontinue if possible (e.g., in COVID-19-associated mucormycosis without other indication)
• If essential (e.g., transplant rejection, autoimmune disease):
  • Reduce to minimum effective dose
  • Consider alternative immunosuppression with less fungal risk

Challenges: Steroid withdrawal may precipitate adrenal insufficiency or disease flare

3. Neutropenia Management

Goal: Restore neutrophil count >500/μL, ideally >1000/μL

Actions:

• G-CSF (Granulocyte Colony-Stimulating Factor):
  • Filgrastim 5 mcg/kg/day SC OR
  • Pegfilgrastim 6 mg SC (single dose, long-acting)
• Granulocyte Transfusions: Consider in refractory neutropenia with life-threatening infection
  • Limited availability, short half-life, transfusion reactions
  • Experimental but may be life-saving

Chemotherapy:

• Delay further myelosuppressive chemotherapy if possible
• Coordinate with haematology-oncology

4. Deferoxamine Cessation

Action: Immediately discontinue deferoxamine if patient is receiving it [15]

Rationale: Acts as a xenosiderophore, providing iron to Mucorales

Alternative Iron Chelation:

• Switch to deferasirox or deferiprone (do NOT enhance Mucorales growth)

5. Transplant Immunosuppression

Goal: Reduce without precipitating rejection

Actions:

• Reduce calcineurin inhibitors (tacrolimus, ciclosporin)
• Reduce or stop antimetabolites (mycophenolate)
• Maintain minimum necessary for graft survival
• Coordinate with transplant team

6. Optimize Nutrition

Goal: Support immune function

Actions:

• Protein-calorie supplementation
• Correct micronutrient deficiencies
• Enteral nutrition preferred over parenteral

---

9.4 Adjunctive Therapies

Hyperbaric Oxygen Therapy (HBOT)

Rationale:

• Enhances tissue oxygenation in ischaemic/necrotic areas
• Improves neutrophil oxidative killing
• May inhibit fungal growth (Mucorales are facultative anaerobes)

Evidence:

• Retrospective case series suggest benefit [2]
• No randomized controlled trials
• Typically used as adjunct in refractory or severe cases

Protocol:

• 2-2.5 ATA (atmospheres) for 90-120 minutes
• Daily sessions for 20-30 treatments

Considerations:

• Availability limited
• Requires stable patient (cannot use in critically ill)
• Risk of barotrauma, oxygen toxicity

Recommendation: Consider as adjunct in selected cases, particularly if surgical debridement suboptimal or extensive tissue necrosis

Cytokine Immunotherapy (Experimental)

• Interferon-gamma (IFN-γ): Enhances macrophage activity (case reports)
• GM-CSF: Enhances neutrophil function (used in some centres)
• Deferasirox: May have direct antifungal effect beyond iron chelation (investigational)

Status: No high-quality evidence; reserved for salvage/compassionate use

---

9.5 Multidisciplinary Care

Essential Team Members:

1. Infectious Diseases - antifungal management
2. ENT/Head-Neck Surgery - surgical debridement (rhinocerebral)
3. Ophthalmology - orbital assessment, vision monitoring
4. Neurosurgery - intracranial extension
5. Cardiothoracic Surgery - pulmonary resection
6. Haematology - neutropenia, underlying malignancy
7. Endocrinology - DKA management
8. Critical Care - ICU support
9. Pharmacy - drug dosing, monitoring, interactions
10. Palliative Care - if prognosis poor/extensive disease

Communication: Daily multidisciplinary rounds during acute phase

---

9.6 Special Populations

Pregnancy

• Mucormycosis in pregnancy is rare but reported
• Amphotericin B: Safe in pregnancy (FDA Category B)
• Azoles: Teratogenic (avoid in 1st trimester if possible)
• Surgery: Proceed as in non-pregnant patients

Paediatrics

• Same principles apply
• Dosing: Weight-based (same mg/kg as adults)
• Neonatal GI mucormycosis: Often catastrophic, high mortality

Renal Impairment

• Amphotericin nephrotoxicity is cumulative
• Consider early switch to isavuconazole if renal function worsening
• Liposomal formulation preferred over deoxycholate

---

9.7 Treatment Algorithm Summary

Suspected Mucormycosis
         ↓
Immediate Actions (within 6 hours):
  • Liposomal amphotericin B 5-10 mg/kg IV
  • CT/MRI imaging
  • Tissue biopsy (nasal endoscopy / bronch / skin)
  • Correct acidosis/DKA
  • Stop deferoxamine, reduce steroids
         ↓
Histopathology: Broad aseptate hyphae
         ↓
Confirmed Mucormycosis
         ↓
TRIPLE THERAPY:
  1. Antifungal: L-AmB 10 mg/kg IV daily (6-12 weeks)
  2. Surgery: Urgent debridement (less than 24h), repeat as needed
  3. Reverse immunosuppression: DKA correction, taper steroids, G-CSF if neutropenic
         ↓
Daily Reassessment:
  • Clinical improvement?
  • Further necrosis (needs repeat surgery)?
  • Imaging improvement (weekly MRI)?
  • Adverse effects (renal, electrolytes)?
         ↓
Week 2-4: If stable, consider:
  • Step down to isavuconazole PO (outpatient)
  • Continue total 8-12 weeks
         ↓
Refractory Disease:
  • Repeat surgery
  • Add posaconazole (combination therapy)
  • HBOT if available
  • Palliative care discussion if disseminated/CNS

---

10. Complications

10.1 Disease-Related Complications

1. Vision Loss (Rhinocerebral)

• Incidence: 30-60% of rhino-orbital cases [12]
• Mechanism: Central retinal artery occlusion, optic nerve infarction, orbital apex syndrome
• Irreversible once established
• Prevention: Urgent recognition and surgery

2. Cavernous Sinus Thrombosis

• Incidence: 20-40% of rhinocerebral with CNS extension [5]
• Features: Bilateral ophthalmoplegia, severe headache, altered mental status
• Mortality: 70-80%

3. Brain Abscess / Stroke

• Incidence: 10-30% of rhinocerebral cases
• Sites: Frontal, temporal lobes (ICA territory)
• Mechanism: Direct extension or septic emboli
• Mortality: 80-100%

4. Internal Carotid Artery Thrombosis/Rupture

• Massive stroke (thrombosis) or fatal haemorrhage (rupture)
• Mortality: >90%

5. Massive Haemoptysis (Pulmonary)

• Incidence: 10-20% of pulmonary cases [11]
• Mechanism: Vessel wall necrosis
• Management: Bronchial artery embolization, surgery (if feasible)
• Can be acutely fatal

6. Bowel Perforation (GI)

• Incidence: Common in GI mucormycosis
• Peritonitis, septic shock
• Mortality: >85%

7. Dissemination

• From any primary site
• Multi-organ failure
• Mortality: 90-100%

10.2 Treatment-Related Complications

Amphotericin B Toxicity

Nephrotoxicity (Most Common):

• Incidence: 30-60% (depending on formulation and dose)
• Mechanism: Renal vasoconstriction, direct tubular toxicity
• Monitoring: SCr, eGFR
• Management:
  • Hydration (0.9% saline pre-infusion)
  • Liposomal formulation (less toxic)
  • Dose reduction if SCr rising
  • Consider switch to azole

Electrolyte Disturbances:

• Hypokalaemia (40-60%): Renal potassium wasting
• Hypomagnesaemia (30-50%)
• Management: Aggressive supplementation (KCl, MgSO4)

Infusion Reactions:

• Incidence: 20-50%
• Features: Fever, rigors, hypotension, nausea
• Management: Premedication (paracetamol, antihistamine), slow infusion

Anaemia:

• Incidence: 50-70% (dose-dependent)
• Mechanism: Decreased erythropoietin production
• Management: Transfusion if symptomatic, consider erythropoietin

Surgical Complications

Disfigurement:

• Facial deformity (maxillectomy)
• Loss of vision (orbital exenteration)
• Psychological impact
• Management: Prosthetics, reconstructive surgery (after infection cleared)

Bleeding:

• Intraoperative and postoperative
• Risk increased by thrombocytopenia (underlying disease)
• May require transfusion, repeat surgery

Infection:

• Secondary bacterial infection of surgical site
• Requires antibiotics

CSF Leak (Skull Base Surgery):

• Risk with extensive skull base debridement
• May require repair

---

11. Prognosis and Outcomes

Overall Mortality

Prognostic Factors

Favourable Prognostic Factors

1. Early diagnosis and treatment (within 5 days of symptom onset)
2. Localized disease (single site, no CNS)
3. Complete surgical resection (negative margins)
4. Reversal of immunosuppression (DKA corrected, neutrophils recovered)
5. Cutaneous form (isolated, no dissemination)
6. No underlying haematological malignancy

Poor Prognostic Factors [5,6]

1. CNS involvement (brain abscess, cavernous sinus thrombosis)
2. Disseminated disease
3. Delayed diagnosis/treatment (>6 days)
4. No surgical intervention
5. Persistent immunosuppression (uncontrolled DKA, ongoing neutropenia, uncontrolled malignancy)
6. Bilateral sinus involvement
7. Facial nerve palsy (suggests extensive skull base involvement)
8. Pulmonary form in haematology patients
9. Gastrointestinal form

Long-Term Outcomes in Survivors

Functional Impairment:

• Vision loss: 30-60% of rhino-orbital survivors have permanent blindness [12]
• Cranial nerve deficits: Persistent ophthalmoplegia, facial numbness
• Disfigurement: Post-surgical (maxillectomy, exenteration)
• Chronic sinusitis: Require ongoing surveillance

Relapse:

• Incidence: 10-20% [2]
• Risk factors: Incomplete surgical resection, persistent immunosuppression, inadequate antifungal duration
• Management: Repeat surgery + prolonged antifungals

Quality of Life:

• Significantly impaired due to disfigurement, functional deficits
• Psychological support, reconstructive surgery important

Surveillance After Treatment

Duration: Minimum 12 months, longer if immunosuppression ongoing

Schedule:

• Clinical assessment: Monthly for 3 months, then every 3 months
• MRI: At 3 months, 6 months, 12 months (or if new symptoms)
• Antifungal therapy: Typically 8-12 weeks minimum

Red Flags for Relapse:

• Recurrent facial pain
• New nasal discharge or crusting
• Worsening vision or new ophthalmoplegia
• New imaging findings

---

12. Prevention and Screening

Primary Prevention

Environmental Control (Limited Efficacy):

• HEPA filtration in high-risk patient areas (haematology wards, transplant units)
• Positive-pressure rooms
• Minimize exposure to construction, soil, decaying organic matter

Limitation: Mucorales spores are ubiquitous; complete avoidance impossible

Antifungal Prophylaxis

Indications (Controversial):

• Very high-risk patients:
  • Acute myeloid leukaemia with prolonged neutropenia
  • Allogeneic HSCT recipients
  • Patients with prior mucormycosis (secondary prophylaxis)

Agents:

• Posaconazole 300 mg PO daily (delayed-release tablet or IV)
  • Shown to reduce invasive fungal infections (including mucormycosis) in AML/MDS [19]
  • Requires therapeutic drug monitoring (trough >1 mg/L)

Limitations:

• No RCT specifically for mucormycosis prevention
• Not routinely recommended in all at-risk patients
• Does not eliminate risk

Risk Factor Modification

Key Strategies:

1. Optimize diabetes control - target HbA1c less than 7%, prevent DKA
2. Minimize corticosteroid use - lowest effective dose, shortest duration
3. Deferoxamine avoidance - use alternative iron chelators (deferasirox) in thalassaemia, iron overload
4. Early neutrophil recovery - G-CSF in appropriate patients

Screening

No routine screening recommended (low yield, not cost-effective)

Surveillance in High-Risk:

• Education: Warn patients of symptoms (facial pain, nasal discharge, eye symptoms)
• Low threshold for imaging (CT/MRI) if symptoms develop
• Prompt biopsy of suspicious lesions

---

13. Common Exam Questions and Viva Points

Common Exam Questions

1. "What are the causes of mucormycosis?"

Model Answer: "Mucormycosis is caused by fungi of the order Mucorales, most commonly Rhizopus species. It occurs almost exclusively in immunocompromised patients. The key risk factors are uncontrolled diabetes mellitus, particularly diabetic ketoacidosis, which is the most common predisposing factor worldwide. Other major risk factors include haematological malignancies with prolonged neutropenia, high-dose corticosteroid therapy, solid organ or stem cell transplantation, and iron overload states, particularly in patients receiving deferoxamine. [1,3,4]"

2. "How does diabetic ketoacidosis predispose to mucormycosis?"

Model Answer: "DKA creates multiple conditions that favour Mucorales growth. First, the acidosis causes dissociation of iron from transferrin, resulting in elevated free serum iron, which the fungi use as an essential growth factor. Second, ketone bodies such as β-hydroxybutyrate directly enhance fungal growth. Third, hyperglycaemia impairs neutrophil chemotaxis and phagocytosis. Finally, acidosis upregulates GRP78 expression on endothelial cells, which serves as the receptor for fungal adhesion molecules, facilitating angioinvasion. [17,18]"

3. "How do you distinguish mucormycosis from aspergillosis on histopathology?"

Model Answer: "There are four key distinguishing features. First, hyphal width: Mucorales have broad hyphae (6-25 micrometres) whereas Aspergillus has narrow hyphae (3-6 micrometres). Second, septation: Mucorales are aseptate or irregularly septate, while Aspergillus has regular septae. Third, branching pattern: Mucorales show right-angle or irregular branching, whereas Aspergillus shows acute-angle dichotomous branching. Fourth, both demonstrate angioinvasion. These features are best seen on PAS or GMS stains. [1,2]"

4. "What is the management of rhinocerebral mucormycosis?"

Model Answer: "Management is based on triple therapy: antifungal treatment, surgical debridement, and reversal of immunosuppression. First, I would start high-dose liposomal amphotericin B at 10 mg/kg IV daily immediately. Second, I would arrange urgent surgical debridement within 24 hours—the goal is to remove all necrotic tissue until bleeding viable tissue is reached, often requiring repeat procedures. Third, I would aggressively correct the underlying risk factor: in DKA, correct the acidosis and achieve euglycaemia; if on steroids, taper as rapidly as possible; if neutropenic, give G-CSF. All three components are essential for survival. [1,2,5]"

5. "Why must voriconazole be avoided in mucormycosis?"

Model Answer: "Voriconazole has NO antifungal activity against Mucorales fungi. Using voriconazole empirically for a suspected mould infection can be fatal if the patient actually has mucormycosis, as it delays appropriate therapy with amphotericin B while the infection progresses. In fact, widespread use of voriconazole prophylaxis and empiric therapy in haematology units has been associated with increased incidence of breakthrough mucormycosis. The only active agents are amphotericin B, isavuconazole, and posaconazole. [19]"

Viva Preparation Points

Opening Statement: "Mucormycosis is a rare, life-threatening angioinvasive fungal infection caused by moulds of the order Mucorales, most commonly Rhizopus species. It predominantly affects severely immunocompromised patients, with diabetic ketoacidosis being the leading risk factor worldwide. The hallmark is rapid vascular invasion leading to thrombosis and tissue necrosis, manifesting as black necrotic eschars. Mortality is 50-80% despite optimal therapy. [1,5,6]"

Key Statistics to Memorize:

• Overall mortality: 54% (range 46-84%)
• Rhinocerebral form: 40-49% of cases, 30-80% mortality
• Pulmonary form: 20-30% of cases, 60-90% mortality
• Disseminated form: 6-12% of cases, 90-100% mortality
• Surgery reduces mortality from 83% to 57% [5]
• DKA present in 40-88% of rhinocerebral cases [9,12]

Classification System: Anatomical - Rhinocerebral (40-49%), Pulmonary (20-30%), Cutaneous (10-16%), Gastrointestinal (2-11%), Disseminated (6-12%)

First-Line Treatment with Evidence: "Liposomal amphotericin B 5-10 mg/kg IV daily for minimum 6 weeks, combined with urgent surgical debridement and correction of underlying immunosuppression. ECMM/ISHAM 2019 guidelines strongly recommend this triple therapy approach. [1]"

What Gets You Failed:

• Suggesting voriconazole has activity (it doesn't)
• Not mentioning surgery (antifungals alone are insufficient)
• Not recognizing DKA as key risk factor
• Describing narrow septate hyphae (that's Aspergillus)
• Waiting for culture before starting treatment (low yield, delays therapy)

Model Answer to Complex Scenario

Q: A 52-year-old woman with AML on chemotherapy develops fever and cough. CT chest shows a cavitating lung lesion. BAL is performed. How would you approach this?

A: "This patient has multiple risk factors for invasive fungal infection: AML, chemotherapy-induced neutropenia. The cavitating lung lesion suggests an angioinvasive process. My differential includes invasive aspergillosis and mucormycosis, as well as bacterial causes.

I would immediately send BAL for fungal culture and histopathology, but would NOT wait for results before starting treatment. While Aspergillus is more common in this population, I must consider mucormycosis because voriconazole—commonly used for presumed aspergillosis—has no activity against Mucorales and could be fatal if the diagnosis is actually mucormycosis.

Given the diagnostic uncertainty and the need for coverage of both pathogens, I would start liposomal amphotericin B 5 mg/kg IV daily, as it covers both Aspergillus and Mucorales. I would NOT start voriconazole empirically. Once histopathology returns—if it shows broad aseptate hyphae with right-angle branching, confirming mucormycosis—I would increase amphotericin to 10 mg/kg daily and urgently consult cardiothoracic surgery for consideration of lobectomy if the lesion is localized and the patient is stable enough. If histopathology shows narrow septate hyphae with acute-angle branching, confirming aspergillosis, I would switch to voriconazole.

I would also review her galactomannan assay—if negative despite probable invasive fungal infection, this also raises suspicion for mucormycosis. Throughout, I would coordinate with haematology for G-CSF to accelerate neutrophil recovery."

---

14. Patient and Layperson Explanation

What is Mucormycosis (Black Fungus)?

Mucormycosis, sometimes called "black fungus," is a very rare but serious infection caused by a type of mould that lives in soil, on plants, and in decaying matter. Most people breathe in tiny spores from this mould every day without any problem because a healthy immune system quickly destroys them.

However, if your immune system is weak—especially if you have uncontrolled diabetes with very high acid levels in your blood (called diabetic ketoacidosis or DKA), or if you're on strong medications that suppress your immune system—the mould can grow rapidly in your body.

Why is it called "Black Fungus"?

As the mould grows, it invades blood vessels and blocks them, cutting off blood supply to the surrounding tissue. This causes the tissue to die and turn black (like frostbite). This black dead tissue (called an eschar) is often the first visible sign of the infection, commonly appearing on the nose, roof of the mouth, or face.

How dangerous is it?

Mucormycosis is extremely serious. Even with the best treatment, about half of patients do not survive. The infection spreads very quickly from the nose to the eyes and brain within days if not treated urgently. That's why it's considered a medical emergency.

How is it treated?

Treatment requires a combination of three things working together:

1. Strong antifungal medication: A powerful drug called amphotericin B is given through a drip into your veins, usually for 6-12 weeks. This drug can have side effects on your kidneys, so doctors monitor you very closely.

2. Surgery: This is the hardest part to accept but is absolutely essential. Surgeons must cut away ALL the dead and infected tissue to stop the infection from spreading. Sometimes this means removing parts of the nose, palate, or even the eye if it's already affected and vision is lost. It sounds drastic, but it saves lives. The surgery often needs to be repeated every day or two until no more infected tissue is found.

3. Fixing the underlying problem: If you have diabetes, we need to bring your blood sugar under control and fix the acid imbalance. If you're on steroids or other immune-suppressing drugs, we need to reduce or stop them if possible.

All three parts are necessary. Medicine alone doesn't work. Surgery alone doesn't work. You need both, plus fixing the immune system problem.

What can I expect?

The treatment is intensive and often requires a long hospital stay in the intensive care unit. The surgery can be disfiguring, and you may need help from plastic surgeons later to improve appearance and function. Recovery takes months, and you'll need close follow-up to make sure the infection doesn't come back.

Can it be prevented?

If you have diabetes, the most important thing is to keep your blood sugar well-controlled and avoid diabetic ketoacidosis. If you're on immune-suppressing medications, follow your doctor's advice carefully and report any new symptoms immediately—especially facial pain, nasal discharge, or eye problems.

---

15. References

1. Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):e405-e421. doi:10.1016/S1473-3099(19)30312-3

2. Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433-444. doi:10.3324/haematol.2016.152900

3. Jeong W, Keighley C, Wolfe R, et al. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26-34. doi:10.1016/j.cmi.2018.07.011

4. Prakash H, Chakrabarti A. Global epidemiology of mucormycosis. J Fungi (Basel). 2019;5(1):26. doi:10.3390/jof5010026

5. Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005;41(5):634-653. doi:10.1086/432579

6. Jeong W, Keighley C, Wolfe R, et al. Contemporary management and clinical outcomes of mucormycosis: a systematic review and meta-analysis of case reports. Int J Antimicrob Agents. 2019;53(5):589-597. doi:10.1016/j.ijantimicag.2019.01.002

7. Skiada A, Pavleas I, Drogari-Apiranthitou M. Epidemiology and diagnosis of mucormycosis: an update. J Fungi (Basel). 2020;6(4):265. doi:10.3390/jof6040265

8. Kontoyiannis DP, Yang H, Song J, et al. Prevalence, clinical and economic burden of mucormycosis-related hospitalizations in the United States: a retrospective study. BMC Infect Dis. 2016;16:730. doi:10.1186/s12879-016-2023-z

9. Chakrabarti A, Das A, Mandal J, et al. The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus. Med Mycol. 2006;44(4):335-342. doi:10.1080/13693780500464930

10. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146. doi:10.1016/j.dsx.2021.05.019

11. Chamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clin Infect Dis. 2005;41(1):60-66. doi:10.1086/430710

12. Honavar SG. Code Mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol. 2021;69(6):1361-1365. doi:10.4103/ijo.IJO_1165_21

13. Kontoyiannis DP, Marr KA, Park BJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50(8):1091-1100. doi:10.1086/651263

14. Lewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiol. 2013;8(9):1163-1175. doi:10.2217/fmb.13.78

15. Ibrahim AS, Spellberg B, Edwards J Jr. Iron acquisition: a novel perspective on mucormycosis pathogenesis and treatment. Curr Opin Infect Dis. 2008;21(6):620-625. doi:10.1097/QCO.0b013e3283165fd1

16. Neblett Fanfair R, Benedict K, Bos J, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367(23):2214-2225. doi:10.1056/NEJMoa1204781

17. Gebremariam T, Liu M, Luo G, et al. CotH3 mediates fungal invasion of host cells during mucormycosis. J Clin Invest. 2014;124(1):237-250. doi:10.1172/JCI71349

18. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis. 2008;47(4):503-509. doi:10.1086/590004

19. Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America. Clin Infect Dis. 2016;63(4):e1-e60. doi:10.1093/cid/ciw326

20. Groppo ER, El-Sayed IH, Aiken AH, Glastonbury CM. Computed tomography and magnetic resonance imaging characteristics of acute invasive fungal sinusitis. Arch Otolaryngol Head Neck Surg. 2011;137(10):1005-1010. doi:10.1001/archoto.2011.170